91 related articles for article (PubMed ID: 12722404)
61. Hemodialysis procedure does not affect the levels of sICAM-1 and sVCAM-1 in patients with end stage renal disease.
Liakopoulos V; Eleftheriadis T; Kyropoulos T; Voliotis G; Potamianos S; Zengos N; Stefanidis I; Heintz B
Ren Fail; 2005; 27(3):315-21. PubMed ID: 15957549
[TBL] [Abstract][Full Text] [Related]
62. [Serum levels of soluble intercellular molecule 1 (sICAM-1) in endometriosis].
Leng J; Lang J; Zhao D; Liu D
Zhonghua Yi Xue Za Zhi; 2002 Feb; 82(3):189-90. PubMed ID: 11953158
[TBL] [Abstract][Full Text] [Related]
63. [Comparison of cathepsin-B-like activity and CA 125 assays use in ovarian cancer diagnosis].
Warwas M; Gerber J; Haczyńska H; Lukasik-Lemańska K
Ginekol Pol; 2000 May; 71(5):400-5. PubMed ID: 10943039
[TBL] [Abstract][Full Text] [Related]
64. Re: Assessment of plasma DNA levels, allelic imbalance, and CA 125 as diagnostic tests for cancer.
Pisal N; Sindos M; Singer A
J Natl Cancer Inst; 2003 Feb; 95(4):331; author reply 331-2. PubMed ID: 12591991
[No Abstract] [Full Text] [Related]
65. Cerebrospinal fluid and serum IL-8, CCL2, and ICAM-1 concentrations in astrocytic brain tumor patients.
Koper OM; Kamińska J; Sawicki K; Reszeć J; Rutkowski R; Jadeszko M; Mariak Z; Dymicka-Piekarska V; Kemona H
Ir J Med Sci; 2018 Aug; 187(3):767-775. PubMed ID: 29086194
[TBL] [Abstract][Full Text] [Related]
66. Trial of isotretinoin and calcitriol monitored by CA 125 in patients with ovarian cancer.
Rustin GJ; Quinnell TG; Johnson J; Clarke H; Nelstrop AE; Bollag W
Br J Cancer; 1996 Nov; 74(9):1479-81. PubMed ID: 8912548
[TBL] [Abstract][Full Text] [Related]
67. Serum levels of interleukin-18 and sICAM-1 in patients affected by breast cancer: preliminary considerations.
Merendino RA; Gangemi S; Ruello A; Bene A; Losi E; Lonbardo G; Purello-Dambrosio F
Int J Biol Markers; 2001; 16(2):126-9. PubMed ID: 11471895
[TBL] [Abstract][Full Text] [Related]
68. Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer).
Rustin GJ; Quinn M; Thigpen T; du Bois A; Pujade-Lauraine E; Jakobsen A; Eisenhauer E; Sagae S; Greven K; Vergote I; Cervantes A; Vermorken J
J Natl Cancer Inst; 2004 Mar; 96(6):487-8. PubMed ID: 15026475
[No Abstract] [Full Text] [Related]
69. Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup.
Vergote I; Rustin GJ; Eisenhauer EA; Kristensen GB; Pujade-Lauraine E; Parmar MK; Friedlander M; Jakobsen A; Vermorken JB
J Natl Cancer Inst; 2000 Sep; 92(18):1534-5. PubMed ID: 10995813
[No Abstract] [Full Text] [Related]
70. [Challenge of evidence-based medicine: sense and non-sense of diagnostic tests in gynecology].
Sehouli J; Stengel D; Hindenburg J; Camara O; Porzsolt F; Lichtenegger W;
Zentralbl Gynakol; 2001 Mar; 123(3):127-31. PubMed ID: 11340951
[TBL] [Abstract][Full Text] [Related]
71. Increased CA 125 in tuberculous peritonitis.
Collazos J
Gut; 1995 Aug; 37(2):297. PubMed ID: 7557589
[No Abstract] [Full Text] [Related]
72. Benign conditions associated with raised serum CA-125 concentration.
Buamah P
J Surg Oncol; 2000 Dec; 75(4):264-5. PubMed ID: 11135268
[TBL] [Abstract][Full Text] [Related]
73. Can rumors cause cancer?
Jones J
J Natl Cancer Inst; 2000 Sep; 92(18):1469-71. PubMed ID: 10995800
[No Abstract] [Full Text] [Related]
74. Technical Verification and Assessment of Independent Validation of Biomarker Models for Endometriosis.
O DF; Fassbender A; Van Bree R; Laenen A; Peterse DP; Vanhie A; Waelkens E; D'Hooghe TM
Biomed Res Int; 2019; 2019():3673060. PubMed ID: 31428634
[TBL] [Abstract][Full Text] [Related]
75. Improved blood tests for cancer screening: general or specific?
Cree IA
BMC Cancer; 2011 Nov; 11():499. PubMed ID: 22128772
[TBL] [Abstract][Full Text] [Related]
76. Evaluation of a novel ELISA for the tumor-associated antigen CA 72-4 in patients with ovarian cancer.
Buderath P; Kasimir-Bauer S; Aktas B; Rasch J; Kimmig R; Zeller T; Heubner M
Future Sci OA; 2016 Dec; 2(4):FSO145. PubMed ID: 28116127
[TBL] [Abstract][Full Text] [Related]
77. [Evaluation of serum sICAM-1 amd CA-125 in patients with ovarian tumors--preliminary report].
Rzymski P; Woźniak J; Opala T; Sajdak S; Drews K
Ginekol Pol; 2002 Nov; 73(11):1090-5. PubMed ID: 12722404
[TBL] [Abstract][Full Text] [Related]
78. [Assessment of soluble intracellular adhesion molecule-1 (sICAM-1) in women with benign ovarian tumors].
Rzymski P; Opala T; Woźniak J; Drews K; Sajdak S
Ginekol Pol; 2004 Oct; 75(10):785-92. PubMed ID: 15587910
[TBL] [Abstract][Full Text] [Related]
79. Evaluation of soluble intracellular adhesion molecule-1 (sICAM-1) in benign and malignant ovarian masses.
Opala T; Drews K; Rzymski P; Woźniak J; Sajdak S
Eur J Gynaecol Oncol; 2003; 24(3-4):255-7. PubMed ID: 12807235
[TBL] [Abstract][Full Text] [Related]
80. Serum sICAM-1 (soluble intercellular adhesion molecule-1) and M-CSF (macrophage colony-stimulating growth factor) throughout monitoring of 34 non-serous ovarian cancers.
Callet N; Delaunay J; Pichon MF
Eur J Gynaecol Oncol; 2000; 21(2):135-40. PubMed ID: 10843471
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
